Thor Medical A Stock

Thor Medical A EBIT per Share

The EBIT per Share of Thor Medical A (TRMED.OL) as of Aug 12, 2026 is -0.04 NOK. In the previous year, EBIT per Share was -2.74 NOK — a change of -98.49% (higher).

EBIT per Share

-0.04NOK

YoY

-98.49%

Last updated:

EBIT per Share of Thor Medical A is 2026 -0.04 NOK. EBIT per Share of Thor Medical A was 2025 -2.74 NOK. It decreases by -98.49% higher compared to the previous year.
Access this data via the Eulerpool API

Thor Medical A Stock analysis

What does Thor Medical A do? Nordic Nanovector ASA is a Norwegian biopharmaceutical company specializing in the development and commercialization of therapies for the treatment of lymphoma and other cancers. The company was founded in 2009 by a group of leading scientists in the field of cancer research, focused on developing new and innovative treatment options for cancer. Nordic Nanovector's business model is based on the use of antibodies specifically targeted to cancer cells. An example of this is the drug Betalutin, which contains a radioactive substance that selectively destroys cancer cells. Betalutin has been tested in multiple clinical trials and has shown promising results in the treatment of non-Hodgkin lymphoma. In addition to Betalutin, the company also has another technology platform based on the use of antibodies with high affinity to specific types of cancer. Nordic Nanovector also manufactures a wide range of diagnostic tools that can be used in cancer research. Since its inception, Nordic Nanovector has received numerous national and international awards and prizes for its innovative products and technologies. The company has established relationships with various academic institutions and organizations to advance research and development. In addition to product development, the company has undergone an impressive capital raise to advance the development of these therapies. Nordic Nanovector has received several public and private financings in recent years to support and expand its research activities. In 2015, the company went public on the Oslo Stock Exchange, foregoing the conquest of the US market. The foundation of the company's portfolio is protected by technology patents and product patents. The company has undergone several challenging development and approval steps to gain a competitive advantage over competitors. The goal is to promote long-term growth and availability of the products worldwide. Nordic Nanovector believes that its business model is realized based on innovative technologies in cancer research. With a focus on the development of therapies and diagnostic tools, the company has built significant potential in the industry. The future prospects and growth outlook are positive and are expected to contribute to even greater success for Nordic Nanovector in the future. Thor Medical A is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Thor Medical A stock

EBIT per Share of Thor Medical A is -0.04 NOK in 2026.

EBIT per Share of Thor Medical A changed from -2.74 NOK to -0.04 NOK, representing a -98.49% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Thor Medical A since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

Income Statement — Thor Medical A

All Key Metrics — Thor Medical A